Skip to main content
Erschienen in: Aesthetic Plastic Surgery 2/2018

06.12.2017 | Original Article

The Efficacy and Safety of Early Postoperative Botulinum Toxin A Injection for Facial Scars

verfasst von: Seo H. Lee, Hyung J. Min, Yang W. Kim, Young W. Cheon

Erschienen in: Aesthetic Plastic Surgery | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Scars widen when the underlying musculature pulls apart suture lines, and scars oriented against relaxed skin tension lines are especially susceptible to these distraction forces. Because botulinum toxin A (BTA) induces complete muscle paralysis, the purpose of the current study was to evaluate the effects of BTA using both observer-dependent qualitative assessments and quantitative measurements to verify its beneficial effects on facial scarring.

Methods

Patients with vertical forehead lacerations, treated by primary closure, were randomly assigned to two groups: one (n = 15) received BTA injections within 5 days of primary closure and the other (n = 15) received no further treatment. Vancouver scar scale (VSS) scores and wound width were determined at the 1-month and 6-month follow-up visits. Quantitative color differences between the scar and surrounding normal skin, using the Commission International d’Eclairage L*a*b* color coordinates, were measured and compared by analyzing photographs.

Result

Improved VSS scores, less increase in wound width, and less scar discoloration were noted among patients treated with BTA injections compared with the control group. These differences were observed at the 6-month visit, but not at the 1-month visit.

Conclusion

BTA injection improves scar quality when injected during the early postoperative days.

Level of Evidence I

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.​springer.​com/​00266.
Literatur
1.
Zurück zum Zitat Wilson AM (2006) Use of botulinum toxin type A to prevent widening of facial scars. Plast Reconstr Surg 117(6):1758–1766CrossRefPubMed Wilson AM (2006) Use of botulinum toxin type A to prevent widening of facial scars. Plast Reconstr Surg 117(6):1758–1766CrossRefPubMed
2.
Zurück zum Zitat Sherris DA, Gassner HG (2002) Botulinum toxin to minimize facial scarring. Facial Plast Surg 18(1):35–39CrossRefPubMed Sherris DA, Gassner HG (2002) Botulinum toxin to minimize facial scarring. Facial Plast Surg 18(1):35–39CrossRefPubMed
3.
Zurück zum Zitat Gassner HG, Brissett AE, Otley CC, Boahene DK, Boggust AJ, Weaver AL, Sherris DA (2006) Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc 81(8):1023–1028CrossRefPubMed Gassner HG, Brissett AE, Otley CC, Boahene DK, Boggust AJ, Weaver AL, Sherris DA (2006) Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc 81(8):1023–1028CrossRefPubMed
4.
Zurück zum Zitat Sherris DA, Larrabee WF Jr, Murakami CS (1995) Management of scar contractures, hypertrophic scars, and keloids. Otolaryngol Clin North Am 28:1057–1068PubMed Sherris DA, Larrabee WF Jr, Murakami CS (1995) Management of scar contractures, hypertrophic scars, and keloids. Otolaryngol Clin North Am 28:1057–1068PubMed
5.
Zurück zum Zitat Jablonka EM, Sherris DA, Gassner HG (2012) Botulinum toxin to minimize facial scarring. Facial Plast Surg 28(5):525–535CrossRefPubMed Jablonka EM, Sherris DA, Gassner HG (2012) Botulinum toxin to minimize facial scarring. Facial Plast Surg 28(5):525–535CrossRefPubMed
6.
Zurück zum Zitat Huang W, Foster JA, Rogachefsky AS (2000) Pharmacology of botulinum toxin. J Am Acad Dermatol 43:249–259CrossRefPubMed Huang W, Foster JA, Rogachefsky AS (2000) Pharmacology of botulinum toxin. J Am Acad Dermatol 43:249–259CrossRefPubMed
7.
Zurück zum Zitat Gassner HG, Sherris DA, Otley CC (2000) Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates. Plast Reconstr Surg 105(6):1948–1953CrossRefPubMed Gassner HG, Sherris DA, Otley CC (2000) Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates. Plast Reconstr Surg 105(6):1948–1953CrossRefPubMed
8.
Zurück zum Zitat Ikeda I, Urushihara K, Ono T (2003) A pitfall in clinical photography: the appearance of skin lesions depends upon the illumination device. Arch Dermatol Res 294:438–443CrossRefPubMed Ikeda I, Urushihara K, Ono T (2003) A pitfall in clinical photography: the appearance of skin lesions depends upon the illumination device. Arch Dermatol Res 294:438–443CrossRefPubMed
9.
Zurück zum Zitat Nedelec B, Shankowsky HA, Tredget EE (2000) Rating the resolving hypertrophic scar: comparison of the Vancouver Scar Scale and scar volume. J Burn Care Rehabil 21:205–212CrossRefPubMed Nedelec B, Shankowsky HA, Tredget EE (2000) Rating the resolving hypertrophic scar: comparison of the Vancouver Scar Scale and scar volume. J Burn Care Rehabil 21:205–212CrossRefPubMed
10.
Zurück zum Zitat Cheon YW, Lee WJ, Rah DK (2010) Objective and quantitative evaluation of scar color using the L*a*b* color coordinates. J Craniofac Surg 21:679–684CrossRefPubMed Cheon YW, Lee WJ, Rah DK (2010) Objective and quantitative evaluation of scar color using the L*a*b* color coordinates. J Craniofac Surg 21:679–684CrossRefPubMed
11.
Zurück zum Zitat Due E, Rossen K, Sorensen LT, Kliem A, Karlsmark T, Haedersdal M (2007) Effect of UV irradiation on cutaneous cicatrices: a randomized, controlled, trial with clinical, skin reflectance, histological, immunohistochemical and biochemical evaluations. Acta Derm Venereol 87(1):27–32CrossRefPubMed Due E, Rossen K, Sorensen LT, Kliem A, Karlsmark T, Haedersdal M (2007) Effect of UV irradiation on cutaneous cicatrices: a randomized, controlled, trial with clinical, skin reflectance, histological, immunohistochemical and biochemical evaluations. Acta Derm Venereol 87(1):27–32CrossRefPubMed
12.
Zurück zum Zitat Fagien S (1999) Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. Plast Reconstr Surg 103(2):701–713CrossRefPubMed Fagien S (1999) Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. Plast Reconstr Surg 103(2):701–713CrossRefPubMed
13.
Zurück zum Zitat Ziade M, Domergue S, Batifol D, Jreige R, Sebbane M, Goudot P, Yachouh J (2013) Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomized study. J Plast Reconstr Aesthet Surg 66(2):209–214CrossRefPubMed Ziade M, Domergue S, Batifol D, Jreige R, Sebbane M, Goudot P, Yachouh J (2013) Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomized study. J Plast Reconstr Aesthet Surg 66(2):209–214CrossRefPubMed
14.
Zurück zum Zitat Chadwick S, Heath R, Shah M (2012) Abnormal pigmentation within cutaneous scars: a complication of wound healing. Indian J Plast Surg 45(2):403–411CrossRefPubMedPubMedCentral Chadwick S, Heath R, Shah M (2012) Abnormal pigmentation within cutaneous scars: a complication of wound healing. Indian J Plast Surg 45(2):403–411CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Ortonne JP, Bissett DL (2008) Latest insights into skin hyperpigmentation. J Investig Dermatol Symp Proc 13:10–14CrossRefPubMed Ortonne JP, Bissett DL (2008) Latest insights into skin hyperpigmentation. J Investig Dermatol Symp Proc 13:10–14CrossRefPubMed
16.
Zurück zum Zitat Courtiss EH, Longacre JJ, Destefano GA, Brizic L, Holmstrand K (1963) The placement of elective skin incisions. Plast Reconstr Surg 31:31–44CrossRefPubMed Courtiss EH, Longacre JJ, Destefano GA, Brizic L, Holmstrand K (1963) The placement of elective skin incisions. Plast Reconstr Surg 31:31–44CrossRefPubMed
17.
Zurück zum Zitat Lee BJ, Jeong JH, Wang SG, Lee JC, Goh EK, Kim HW (2009) Effect of botulinum toxin type A on a rat surgical wound model. Clin Exp Otorhinolaryngol 2(1):20–27CrossRefPubMedPubMedCentral Lee BJ, Jeong JH, Wang SG, Lee JC, Goh EK, Kim HW (2009) Effect of botulinum toxin type A on a rat surgical wound model. Clin Exp Otorhinolaryngol 2(1):20–27CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Ward NL, Kavlick KD, Diaconu D, Dawes SM, Michaels KA, Gilbert E (2012) Botulinum neurotoxin A decreases infiltrating cutaneous lymphocytes and improves acanthosis in the KC-Tie2 mouse model. J Incest Dermatol 132(7):1927–1930CrossRef Ward NL, Kavlick KD, Diaconu D, Dawes SM, Michaels KA, Gilbert E (2012) Botulinum neurotoxin A decreases infiltrating cutaneous lymphocytes and improves acanthosis in the KC-Tie2 mouse model. J Incest Dermatol 132(7):1927–1930CrossRef
19.
Zurück zum Zitat Carmichael NM, Dostrovsky JO, Charlton MP (2010) Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin. Pain 149:316–324CrossRefPubMed Carmichael NM, Dostrovsky JO, Charlton MP (2010) Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin. Pain 149:316–324CrossRefPubMed
20.
Zurück zum Zitat Reckenbeil J, Kraus D, Stark H, Rath-Deschner B, Jäger A, Wenghoefer M, Winter J, Götz W (2017) Insulin-like growth factor 1 (IGF1) affects proliferation and differentiation and wound healing processes in an inflammatory environment with p38 controlling early osteoblast differentiation in periodontal ligament cells. Arch Oral Biol 73:142–150CrossRefPubMed Reckenbeil J, Kraus D, Stark H, Rath-Deschner B, Jäger A, Wenghoefer M, Winter J, Götz W (2017) Insulin-like growth factor 1 (IGF1) affects proliferation and differentiation and wound healing processes in an inflammatory environment with p38 controlling early osteoblast differentiation in periodontal ligament cells. Arch Oral Biol 73:142–150CrossRefPubMed
21.
Zurück zum Zitat Wright MC, Cho WJ, Son YJ (2007) Distinct patterns of motor nerve terminal sprouting induced by ciliary neurotrophic factor vs. botulinum toxin. J Comp Neurol 504(1):1–16CrossRefPubMed Wright MC, Cho WJ, Son YJ (2007) Distinct patterns of motor nerve terminal sprouting induced by ciliary neurotrophic factor vs. botulinum toxin. J Comp Neurol 504(1):1–16CrossRefPubMed
22.
Zurück zum Zitat Shaarawy E, Hegazy RA, Abdel Hay RM (2015) Intralesional botulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: a randomized controlled trial. J Cosmet Dermatol 14:161–166CrossRefPubMed Shaarawy E, Hegazy RA, Abdel Hay RM (2015) Intralesional botulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: a randomized controlled trial. J Cosmet Dermatol 14:161–166CrossRefPubMed
23.
Zurück zum Zitat Carruthers J, Carruthers A (2004) The effect of full-face broadband light treatments alone and in combination with bilateral crow’s feet botulinum toxin type A chemodenervation. Dermatol Surg 30(3):355–366PubMed Carruthers J, Carruthers A (2004) The effect of full-face broadband light treatments alone and in combination with bilateral crow’s feet botulinum toxin type A chemodenervation. Dermatol Surg 30(3):355–366PubMed
24.
Zurück zum Zitat Gassner HG, Sherris DA (2000) Addition of an anesthetic agent to enhance the predictability of the effects of botulinum toxin A injection: randomized controlled study. Mayo Clin Proc 75(7):701–704CrossRefPubMed Gassner HG, Sherris DA (2000) Addition of an anesthetic agent to enhance the predictability of the effects of botulinum toxin A injection: randomized controlled study. Mayo Clin Proc 75(7):701–704CrossRefPubMed
25.
Zurück zum Zitat Gassner HG, Sherris DA (2003) Chemoimmobilization: improving predictability in the treatment of facial scars. Plast Reconstr Surg 112(5):1464–1466CrossRefPubMed Gassner HG, Sherris DA (2003) Chemoimmobilization: improving predictability in the treatment of facial scars. Plast Reconstr Surg 112(5):1464–1466CrossRefPubMed
Metadaten
Titel
The Efficacy and Safety of Early Postoperative Botulinum Toxin A Injection for Facial Scars
verfasst von
Seo H. Lee
Hyung J. Min
Yang W. Kim
Young W. Cheon
Publikationsdatum
06.12.2017
Verlag
Springer US
Erschienen in
Aesthetic Plastic Surgery / Ausgabe 2/2018
Print ISSN: 0364-216X
Elektronische ISSN: 1432-5241
DOI
https://doi.org/10.1007/s00266-017-1008-7

Weitere Artikel der Ausgabe 2/2018

Aesthetic Plastic Surgery 2/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.